Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.42) by 61.9 percent. This is a 96.41 percent increase over losses of $(18.94) per share from the same period last year.